Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin lispro solution and insulin lispro protamine suspension - suspension for injection - 100u/ml (3,5mg/ml)

United States - English - NLM (National Library of Medicine)

eli lilly and company - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - lyumjev® is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. lyumjev is contraindicated: - during episodes of hypoglycemia. - in patients with hypersensitivity to insulin lispro-aabc or any of the excipients in lyumjev. risk summary published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day. no adverse effects on embryo/fetal development were observed in offsprin

United States - English - NLM (National Library of Medicine)

a-s medication solutions - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. insulin lispro is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients who are hypersensitive to insulin lispro or to any of the excipients in insulin lispro [see warnings and precautions (5.5)] . risk summary published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3 times the human subcutaneous dose of 1 unit i

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin lispro solution and insulin lispro protamine suspension - suspension for injection - 100iu/ml (3,5mg/ml)

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin lispro solution and insulin lispro protamine suspension - suspension for injection - 100u/ml (3,5mg/ml)

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin lispro solution and insulin lispro protamine suspension - suspension for injection - 100u/ml (3,5mg/ml)

United States - English - NLM (National Library of Medicine)

kamada ltd. - human cytomegalovirus immune globulin (unii: 129l90a25n) (human cytomegalovirus immune globulin - unii:129l90a25n) - cytomegalovirus immune globulin intravenous (human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. in transplants of these organs other than kidney from cmv seropositive donors into seronegative recipients, prophylactic cmv-igiv should be considered in combination with ganciclovir. cytogam® should not be used in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations. persons with selective immunoglobulin a deficiency have the potential for developing antibodies to immunoglobulin a and could have anaphylactic reactions to subsequent administration of blood products that contain immunoglobulin a, including cytogam® .

Israel - English - Ministry of Health

kamada ltd, israel - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents (0-18 years) in:- primary immunodeficiency syndromes (pid) with impaired antibody production- secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of <4 g/l* psaf= failure to mount at least a 2-fold rise in igg antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccinesimmunomodulation in adults, and children and adolescents (0-18 years) in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barré syndrome- kawasaki disease (in conjunction with acetylsalicylic acid)- chronic inflammatory demyelinating polyradiculoneuropathy (cidp)- multifocal motor neuropathy (mmn)

Singapore - English - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human cytomegalovirus immunoglobulin in 50mg/ml human plasma protein (igg ≥ 96%) - injection - 100 u/ml - human cytomegalovirus immunoglobulin in 50mg/ml human plasma protein (igg ≥ 96%) 100 u/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide red; iron oxide yellow; magnesium stearate; dimeticone 100; calcium hydrogen phosphate; titanium dioxide; microcrystalline cellulose; crospovidone; macrogol 400; maize starch; colloidal anhydrous silica - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.